SynthesisLasers in surgery and medicine2025
The 595-nm Wavelength Pulsed Dye Laser for Pediatric Port-Wine Birthmarks and Infantile Hemangiomas: A Systematic Review.
Synthesis in Lasers in surgery and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Efficacy of pro-yellow laser versus cryotherapy in treating cutaneous lesions of Kaposi's sarcoma: a comparative study.Archives of dermatological research · 2025Trial
- Laser Therapy for Cutaneous Vascular Anomalies: Efficacy, Safety, and Innovations.American journal of clinical dermatology · 2026Review
- Topical Timolol Beyond Infancy: A Retrospective Study of Its Use in Persistent Infantile Hemangiomas.Dermatology and therapy · 2026Article
- Combination Therapy With AOPT Intense Pulsed Light (Dual-Band Vascular Filter) and 1064 nm Nd:YAG Laser for Solitary, Superficial Infantile Hemangioma: A Retrospective Study.Journal of cosmetic dermatology · 2026Article
- In search for optimal schedule during long term treatment of port wine birthmarks - data from single center retrospective cohort study with a small prospective extension.Lasers in medical science · 2026Article
- A numerical study on the effect of laser therapy against port-wine stain by administering artificial red blood cells.Lasers in medical science · 2026Article
- Thermoresponsive Hydroxybutyl Chitosan-Assisted Carteolol Delivery with Pulsed Dye Laser for Superficial Infantile Hemangiomas: An Exploratory Randomized Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Hypertrophic Scarring and Keloids: Epidemiology, Molecular Pathogenesis, and Therapeutic Interventions.MedComm · 2025Review
- Carbon dioxide laser ablation as an effective method for treating nodular areas in Port wine stains: a series of two cases.Lasers in medical science · 2025Article
- Efficacy of Sequential Combination of Long-Pulsed Potassium Titanyl Phosphate 532-nm and Quasi Long-Pulsed 1,064-nm Nd:YAG Laser Therapy for Port-Wine Stain Treatment: A Case Report.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionThe 595-nm wavelength pulsed dye laser (PDL) is well-established in the treatment of vascular lesions. In June 2023, it received FDA clearance for the treatment of port-wine birthmarks (PWB) and infantile hemangiomas (IH) in the pediatric population.
objectiveReview the evidence regarding the efficacy, safety, and implications of using PDL for management of pediatric PWB and IH.
methodsA systematic literature search was performed to identify peer-reviewed articles and clinical trials published between July 2002 and December 2022 in which PDL was used to treat pediatric PWB and IH.
resultsAfter application of criteria, 33 journal articles with 7725 total patients were included. Only 16 (0.8%) of the 2,033 patients with PWB and 11 (0.2%) of the 5692 patients with hemangioma reported permanent adverse effects including scarring, keloids, or permanent pigmentation change, and none reported blindness or other serious injury. Good, excellent, or complete clearance after PDL-on average or in greater than 50% of patients-was reported in 17 of 19 studies (89%) that reported these measures for PWB, and seven of the seven studies (100%) for IH.
conclusionThe 595-nm PDL is an excellent treatment option for early intervention in pediatric patients with PWB or IH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.